newsfilter
← Latest News
GlobeNewswire·

Editas Medicine Announces Second Quarter 2025 Results and Business Updates

Company to select lead development candidate in September; on track to file IND by mid-2026 and achieve human proof-of-concept by year-end 2026 First IND/CTA accepted for CD19 HD Allo CAR T program as part of